Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
115.78
+2.93 (2.60%)
Aug 12, 2026, 11:54 AM EDT - Market open
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $71.26M in the quarter ending June 30, 2026, with 46.91% growth. This brings the company's revenue in the last twelve months to $239.92M, up 53.51% year-over-year. In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth.
Revenue (ttm)
$239.92M
Revenue Growth
+53.51%
P/S Ratio
32.38
Revenue / Employee
$579,512
Employees
414
Market Cap
7.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ionis Pharmaceuticals | 874.09M |
| TG Therapeutics | 799.54M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Kymera Therapeutics | 105.00M |
| Crinetics Pharmaceuticals | 42.16M |
| CG Oncology | 6.23M |
RYTM News
- 3 hours ago - Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 7 days ago - Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital - TheFly
- 7 days ago - Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord - TheFly
- 7 days ago - Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi - TheFly
- 7 days ago - Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens - TheFly
- 7 days ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 8 days ago - Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition - Reuters
- 8 days ago - Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts